EMEA-001451-PIP01-13-M01
Key facts
| Invented name |
Ilumetri
|
| Active substance |
tildrakizumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0120/2021
|
| PIP number |
EMEA-001451-PIP01-13-M01
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of psoriasis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Almirall, S.A
E-mail: global.regulatory@almirall.com
Tel: +34 932913000 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|